Honz Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2020
August 24, 2020 at 07:38 am
Share
Honz Pharmaceutical Co., Ltd. announced earnings results for the half year ended June 30, 2020. For the half year, the company announced sales was CNY 411.318 million compared to CNY 522.386 million a year ago. Operating income was CNY 13.829 million compared to CNY 15.750 million a year ago. Net income was CNY 7.450 million compared to CNY 6.366 million a year ago. Basic earnings per share from continuing operations was CNY 0.0166 compared to CNY 0.0141 a year ago.
HONZ PHARMACEUTICAL CO., LTD., formerly HAINAN HONZ PHARMACEUTICAL CO., LTD., is principally engaged in the research, development, production and distribution of drugs for children. The Company provides western medicines and Chinese patent drugs, including antipyretic and analgesic drugs, cold drugs, antibiotics drugs, respiratory system drugs, digestant and arresting convulsion drugs, as well as nutrition drugs, among others. The Company's products include nimesulide granules, cefminox sodium for injection, Zhike Juhong granules, Ganmao Qingre granules, artificial cow-bezoar and chlorphenamine maleate granules, cefaclor granules, carbocisteine granules, Jianerle granules, pediatric four vitaminsand calcium gluconate granules, as well as ribavirin pellets and Norfloxacin capsules for adults.
HONZ PHARMACEUTICAL CO., LTD. 
